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 ABSTRACT
Infantile cystinosis is a rare disorder which left 
untreated results in end -stage renal disease early in 
life. Together with dehydration and electrolyte imbal-
ance due to renal tubular Fanconi syndrome, end-
stage renal disease used to be the leading cause of 
death in children with cystinosis. Specific therapy 
with cysteamine (cystine -depleting agent) has 
changed the course of this disease. Instead of being 
fatal in childhood, it can nowadays be considered a 
multisystemic adult disorder. The authors report a 
case of a child diagnosed with Fanconi syndrome at 
14 months of age and infantile cystinosis at 19 
months of age in whom oral cysteamine treatment 
led to a good outcome during childhood.
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 INTRODUCTION
Cystinosis is a rare autosomal recessive lyso-
somal storage disorder caused by impaired transport 
of the amino acid cystine from cellular lysosomes. 
It has an estimated annual incidence of 1 case per 
100,000 to 200,000 live births and the causative 
gene, CTNS, mapped in chromosome 17p13, encodes 
the protein cystinosin1,2. Early findings of the classic 
infantile form include Fanconi syndrome, rickets, 
impaired growth, hypothyroidism and corneal 
crystals1 -4. Without specific therapy, deterioration of 
the renal function results in renal failure in the first 
decade of life2. Specific therapy with cysteamine has 
proven efficacious. By inhibiting the accumulations 
of cystine, it not only prevents or delays renal dete-
rioration, but also enhances growth, heals rickets 
and prevents several of the early and late non -renal 
complications of cystinosis2.
In this article the authors report a case of infantile 
cystinosis with a good clinical outcome.
 CASE REPORT
A Caucasian boy, with no known family history of 
cystinosis, product of a non -consanguineous union, 
was delivered after a full -term uneventful pregnancy. 
He had a normal birth weight and height. By 6 months 
of old, nappy rash and a change in urine smell 
motivated several urinalyses. He was presented to 
the paediatric nephrology outpatients department at 
14 months old with persistent glycosuria. At this 
time, with a proper caloric intake, he was found to 
have growth under percentile five, widening of the 
wrists and genus valgus, without any other clinical 
symptom or sign. Laboratory investigation estab-
lished the diagnosis of Fanconi syndrome with 
polyuria, loss of glucose, phosphate, calcium, uric 
acid and amino acids in the urine, metabolic acido-
sis, with a normal anion gap, and an HCO3 urinary 
excretion fraction of 14%. The bone age was equiv-
alent to a child of six months. He was started on 
supportive therapy with sodium and potassium cit-
rate, phosphate, calcitriol and indomethacin with 
clinical, laboratory and radiology improvement. At 
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the age of 19 months, a leucocyte cystine measure-
ment of 3.2 nmol half -cystine per mg protein set the 
diagnosis of cystinosis. In the DNA assay, a homozy-
gotic 57 -kbA deletion in the CTNS gene was found. 
Specific therapy with phosphocysteamine, which was 
later replaced by cysteamine at a dose of 60mg/Kg 
of body weight per day, given every six hours, was 
started. Aiming to maintain cystine levels below 1.0 
nmol half -cystine per mg protein, cysteamine dose 
was adjusted according to yearly leucocyte cystine 
measurements. During the following years, until his 
present age of 18 years old, there was a progressive 
improvement of his bone deformities and his growth 
proceeded near the 25th percentile. He had a normal 
pubertal development and thyroid hormones and 
transaminases remained in the normal ranges. At 
the age of two years old he appeared with com-
plaints of photophobia. Corneal cystine crystals were 
manifest and topical cysteamine therapy started. Due 
to low compliance, he maintained photophobia 
complaints until he was 14 years old. At the present 
time he has no crystals in the cornea. The glomeru-
lar filtration rate (GFR) was normal until the age of 
17, with a present value of 60 ml/min/1,73m2. Renal 
ultrasound has shown kidney stones and increased 
cortical echogenicity since the age of 11 years old. 
At the age of 15 years he was submitted to a bilat-
eral proximal tibial epiphysiodesis to correct genus 
valgus with sucess.
 DISCUSSION
Renal manifestations dominate the clinical pre-
sentation and course of infantile cystinosis3. Our 
patient was normal at birth and the typical poor 
growth and rickets were detected by 14 months. At 
this age he was diagnosed with Fanconi syndrome 
and rickets, which is the classic presentation of 
cystinosis and occurs in 95% of the cases between 
the sixth and twelfth month of life1,3. The leucocyte 
cystine measurement set the diagnosis and the 
homozygotic 57 -kbA deletion in the CTNS gene 
detected is the most common mutation causing the 
classic form of this disorder4.
In the absence of specific treatment, creatinine 
clearance decreases inexorably and end -stage renal 
disease develops in the first decade of life1,5. In 
these cases, renal transplantation is life saving and 
disease does not recur in the kidney if native kidneys 
are extirpated2,6. Nevertheless, cystine storage con-
tinues in non -renal tissues2,6. Instead, long term oral 
administration of cysteamine addresses the cause 
of the disease, depleting the cells of 95% of their 
cystine content7. Therefore, when introduced early 
in the course of the disease and taken diligently, 
cysteamine can accomplish the preservation of renal 
function and allow a normal growth rate4,7,8. 
Cysteamine also prevents non -renal early complica-
tions of cystinosis as hypothyroidism8. Indeed, in 
the reported case, with the introduction of cysteam-
ine at 19 month of age, renal function was preserved 
until the age of 17, linear growth increased dra-
matically, with a significant improvement of height 
velocity, and hypothyroidism was avoided. To achieve 
these targets an adequate replacement of renal 
losses, an early and long term treatment with oral 
cysteamine and frequent leucocyte cystine measure-
ments were required. These determinations allow 
cysteamine dose adjustments and evaluation of 
therapy compliance.
Regarding ophthalmic manifestations, crystal 
accumulation in the conjunctiva and cornea, with 
photophobia and pigmentary retinopathy, are the 
earliest complications10. In this case, corneal cystine 
crystals became symptomatic at the age of two 
years. Oral cysteamine do not dissolve corneal cys-
tine crystals but, as published in the literature, 
therapy with frequent topical cysteamine eye drops 
has completely dissolved the crystals11.
The renal transplant and specific therapy with 
cysteamine transformed cystinosis into a chronic 
treatable disease. At this moment our patient has 
no symptomatic late extra renal complication. Nev-
ertheless, with the much longer life span achieved, 
late complications of the disease may come to light. 
Among them are progressive myopathy, central nerv-
ous system disease, arterial hypertension and car-
diomyopathy, diabetes, hypercholesterolemia and 
hepatic and pulmonary involvement6,8,9.
 CONCLUSIONS
This case illustrates the efficacy of therapy with 
oral cysteamine in delaying renal deterioration, 
enhancing growth and preventing early non -renal 
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complications of cystinosis. To achieve these targets, 
early diagnosis, good therapy compliance and fre-
quent dose adjustments are crucial. With the result-
ing longer life expectancy, the clinical course of 
cystinosis has changed from a mainly renal disease 
to a multisystemic disorder with new therapeutic 
challenges. Recent reports show that the frequency 
of diabetes mellitus, myopathy, pulmonary dysfunc-
tion, hypothyroidism and death decreased as time 
on cysteamine therapy increased, and increased with 
time off cysteamine treatment9. Despite diligent oral 
cysteamine therapy, cysteamine hydrochloride eye 
drops given 10 -12 times per day are required to 
relieve photophobia within weeks and dissolve cor-
neal crystals within months.
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